Kailera reported double-digit weight loss from its investigational “triple-G” obesity shot in an early Phase 1 dosing study conducted with partner Hengrui Pharmaceuticals in China. The company said participants lost up to 16% of body weight over 12 weeks, supporting the asset’s progression toward Kailera-led development outside China. The data center on KAI-4729, a triple-agonist designed to simulate GLP-1 and GIP signaling while also engaging a glucagon-like pathway. Kailera said it will run its own Phase 1 study abroad, with pivotal data timelines extending into 2027, while Hengrui advances the program in China. Analysts framed the readout as more favorable than early disclosures for Eli Lilly’s triple-agonist comparator at the same time point, though the companies remain at different stages. Kailera’s strategy leverages China’s regulatory pathway and an in-licensing structure with Hengrui. The update lands as obesity drug competition intensifies across GLP-1, dual agonists, and triple-hormone approaches, with market expectations anchored to superior weight-loss durability and tolerability.